| <P style="MARGIN: 0cm 0cm 0pt; TEXT-INDENT: 24pt; TEXT-ALIGN: left; mso-pagination: widow-orphan; mso-char-indent-count: 2.0; mso-line-height-alt: 0pt" align=left><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: 宋体; mso-font-kerning: 0pt; mso-bidi-font-family: Arial; mso-hansi-font-family: Arial; mso-ascii-font-family: Arial">印度</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; mso-font-kerning: 0pt" XML:LANG="EN-US">Ampio</SPAN><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: 宋体; mso-font-kerning: 0pt; mso-bidi-font-family: Arial; mso-hansi-font-family: Arial; mso-ascii-font-family: Arial">制药有限公司称：它的早泄治疗药物在欧洲开展的一项后期临床试验中获得有意义的结果。该药名为</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; mso-font-kerning: 0pt" XML:LANG="EN-US">Zertane</SPAN><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: 宋体; mso-font-kerning: 0pt; mso-bidi-font-family: Arial; mso-hansi-font-family: Arial; mso-ascii-font-family: Arial">，可于需要时在性活动之前服用，无需每日服药。该公司表示：这项试验结果分析出乎预期，这些数据将可能成为该药在欧盟注册获准的依据。没有提及在美国申请的计划。</SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt; TEXT-INDENT: 24pt; TEXT-ALIGN: left; mso-pagination: widow-orphan; mso-char-indent-count: 2.0; mso-line-height-alt: 0pt" align=left><SPAN lang=EN-US style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; mso-font-kerning: 0pt" XML:LANG="EN-US">Zertane</SPAN><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: 宋体; mso-font-kerning: 0pt; mso-bidi-font-family: Arial; mso-hansi-font-family: Arial; mso-ascii-font-family: Arial">的活性成分为盐酸曲马多（</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; mso-font-kerning: 0pt" XML:LANG="EN-US">tramadol hydrocloride</SPAN><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: 宋体; mso-font-kerning: 0pt; mso-bidi-font-family: Arial; mso-hansi-font-family: Arial; mso-ascii-font-family: Arial">），它在上世纪</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; mso-font-kerning: 0pt" XML:LANG="EN-US">90</SPAN><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: 宋体; mso-font-kerning: 0pt; mso-bidi-font-family: Arial; mso-hansi-font-family: Arial; mso-ascii-font-family: Arial">年代中期被批准用于缓解疼痛。</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; mso-font-kerning: 0pt" XML:LANG="EN-US">Ampio</SPAN><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: 宋体; mso-font-kerning: 0pt; mso-bidi-font-family: Arial; mso-hansi-font-family: Arial; mso-ascii-font-family: Arial">公司试图对先前获准的一些药物寻找新的适应症。</SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt; TEXT-INDENT: 24pt; TEXT-ALIGN: left; mso-pagination: widow-orphan; mso-char-indent-count: 2.0; mso-line-height-alt: 0pt" align=left><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: 宋体; mso-font-kerning: 0pt; mso-bidi-font-family: Arial; mso-hansi-font-family: Arial; mso-ascii-font-family: Arial">早泄是一种最常见的男性性功能障碍，</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; mso-font-kerning: 0pt" XML:LANG="EN-US">年</SPAN><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: 宋体; mso-font-kerning: 0pt; mso-bidi-font-family: Arial; mso-hansi-font-family: Arial; mso-ascii-font-family: Arial">龄</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; mso-font-kerning: 0pt" XML:LANG="EN-US">18</SPAN><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: 宋体; mso-font-kerning: 0pt; mso-bidi-font-family: Arial; mso-hansi-font-family: Arial; mso-ascii-font-family: Arial">至</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; mso-font-kerning: 0pt" XML:LANG="EN-US">75</SPAN><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: 宋体; mso-font-kerning: 0pt; mso-bidi-font-family: Arial; mso-hansi-font-family: Arial; mso-ascii-font-family: Arial">岁的男子约有<SPAN lang=EN-US style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; mso-font-kerning: 0pt" XML:LANG="EN-US">23%</SPAN>受此症困扰。</SPAN></P> |
